Serum procalcitonin for differentiating bacterial infection from disease flares in patients with autoimmune diseases

Journal of Korean Medical Science

Volumn 26, Issue 9, 2011, Pages 1147-1151

  Joo, Kowoon ^a   Park, Won ^a   Lim, Mie Jin ^a   Kwon, Seong Ryul ^a   Yoon, Jiyeol ^a  

^a Inha University Hospital   (South Korea)

Author keywords

Autoimmune diseases; Bacterial infections; C reactive protein; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; CALCITONIN; PROCALCITONIN; PROTEIN PRECURSOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLOOD; FEMALE; HUMAN; MALE; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AREA UNDER CURVE; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; C-REACTIVE PROTEIN; CALCITONIN; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 80052791104     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.9.1147     Document Type: Article

References (26)

1. Sheldon J, Riches PG, Soni M, Jurges E, Gore M, Dadian G, Hobbs JR. Plasma neopterin as an adjunct to C-reactive protein in assessment of infection. Clin Chem 1991; 37: 2038-42.
2. Tamaki K, Kogata Y, Sugiyama D, Nakazawa T, Hatachi S, Kageyama G, Nishimura K, Morinobu A, Kumagai S. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 2008; 35: 114-9.
3. Russwurm S, Oberhoffer M, Zipfel PF, Reinhart K. Procalcitonin: a novel biochemical marker for the mediator-directed therapy of sepsis. Mol Med Today 1999; 5: 286-7.
4. Russwurm S, Stonans I, Stonane E, Wiederhold M, Luber A, Zipfel PF, Deigner HP, Reinhart K. Procalcitonin and CGRP-1 mRNA expression in various human tissues. Shock 2001; 16: 109-12.
5. Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86: 396-404.
6. Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, Limburg PC, ten Duis HJ, Moshage H, Hoekstra HJ, Bijzet J, Zwaveling JH. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000; 28: 458-61.
7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
8. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605-8.
9. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40: 1250-6.
10. Delèvaux I, André M, Colombier M, Albuisson E, Meylheuc F, Bègue RJ, Piette JC, Aumaître O. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 2003; 62: 337-40.
11. Hur M, Moon HW, Yun YM, Kim KH, Kim HS, Lee KM. Comparison of diagnostic utility between procalcitonin and C-reactive protein for the patients with blood culture-positive sepsis. Korean J Lab Med 2009: 29: 529-35.
12. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
13. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
15. Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F. Adult-onset Still's disease. Rheumatol Int 2010; 30: 855-62.
16. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
17. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behçet's disease activity index. Rheumatology (Oxford) 2004; 43: 73-8.
18. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C. EULAR Sjögren's syndrome disease activity index (ESSDAI): development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010; 69: 1103-9.
19. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, Cerinic MM, Belch JF, Black CM, Bruhlmann P, Czirják L, De Luca A, Drosos AA, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Rosada M, Scorza R, Stork J, Sysa A, van den Hoogen FH, Vlachoyiannopoulos PJ. European multicentre study to define disease activity criteria for systemic sclerosis: II. identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-8.
20. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C, Aden D. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-8.
21. Lanoix JP, Bourgeois AM, Schmidt J, Desblache J, Salle V, Smail A, Mazière JC, Betsou F, Choukroun G, Duhaut P, Ducroix JP. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 2011; 20: 125-30.
22. Scirè CA, Cavagna L, Perotti C, Bruschi E, Caporali R, Montecucco C. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 2006; 24: 123-8.
23. Chen DY, Chen YM, Ho WL, Chen HH, Shen GH, Lan JL. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis 2009; 68: 1074-5.
24. Kim MH, Lim G, Kang SY, Lee WI, Suh JT, Lee HJ. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J 2011; 52: 276-81.
25. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36: 941-52.
26. Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982; 8: 91-103.